ABSTRACT
In this work we propose a delay differential equation as a lumped parameter or compartmental infectious disease model featuring high descriptive and predictive capability, extremely high adaptability and low computational requirement. Whereas the model has been developed in the context of COVID-19, it is general enough to be applicable mutatis mutandis to other diseases as well. Our fundamental modeling philosophy consists of a decoupling of public health intervention effects, immune response effects and intrinsic infection properties into separate terms. All parameters in the model are directly related to the disease and its management; we can measure or calculate their values a priori basis our knowledge of the phenomena involved, instead of having to extrapolate them from solution curves. Our model can accurately predict the effects of applying or withdrawing interventions, individually or in combination, and can quickly accommodate any newly released information regarding, for example, the infection properties and the immune response to an emerging infectious disease. After demonstrating that the baseline model can successfully explain the COVID-19 case trajectories observed all over the world, we systematically show how the model can be expanded to account for heterogeneous transmissibility, detailed contact tracing drives, mass testing endeavours and immune responses featuring different combinations of limited-time sterilizing immunity, severity-reducing immunity and antibody dependent enhancement.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
There is NO funding to report for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approvals required due to mathematical modeling study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
There is NO data referred to in the manuscript.
